Hybridize Therapeutics

Who we are

Hybridize Therapeutics (2019) is a biotech spin-off from the Leiden University Medical Center with a rich history in research & development in RNA-based therapies. Hybridize’s goal is to help patients overcome untreated diseases. We do this by developing RNA-based therapies, i.e. antisense oligonucleotides. Currently, we are in the pre-clinical phase for our therapy against BK-virus and in the early pre-clinical phase for our therapy against JC-virus. Both viruses are activated in the kidney, the location where our antisense oligonucleotides naturally home to.